# Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

> **NCT02527681** · PHASE1 · TERMINATED · sponsor: **Basilea Pharmaceutica** · enrollment: 15 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Ceftobiprole medocaril

## Key facts

- **NCT ID:** NCT02527681
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-22
- **Primary completion:** 2020-02-25
- **Final completion:** 2020-02-25
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** on July 07, 2020 due to slow enrollment; there were no safety concerns.
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02527681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02527681, "Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02527681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*